Future neuroprotective strategies in the post-thrombolysis era - Neurovascular unit protection and vascular endothelial protection

Tatsushi Kamiya, Koji Abe

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

From an appearance of recombinant tissue plasminogen activator (rt-PA) in the clinical therapy on 2005 in Japan, the therapeutic strategy of ischemic stroke therapy is now changing dramatically. Many experimental data from animal stroke and clinical trials of neuroprotective agents failed to clinical useful therapeutic strategy. A free radical scavenger, edaravone is the first clinical drug for neuroprotection in the world which has been used in almost all ischemic stroke patients in Japan from 2001. Now, it is especially useful in thrombolytic therapy with rt-PA, whereas we still need the newly more effective neuroprotective drugs which can be applied to many ischemic stroke patients. Therefore, we review and describe the future neuroprotective strategies in the post-thrombolysis era.

Original languageEnglish
Pages (from-to)305-315
Number of pages11
JournalClinical Neurology
Volume51
Issue number5
DOIs
Publication statusPublished - May 2011

Keywords

  • Acute ischemic stroke
  • Ischemic cell death
  • Neuroprotection
  • Therapeutic time window
  • Thrombolysis

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Future neuroprotective strategies in the post-thrombolysis era - Neurovascular unit protection and vascular endothelial protection'. Together they form a unique fingerprint.

  • Cite this